It's an important step for the company as it means they remain on track to submit an investigational new drug/clinical trial application by the end of next year.
Avacta's Alastair Smith updates on selection of cancer candidate to take into clinic
Quick facts: Avacta Group PLC
Price: 126.99 GBX
Market Cap: £320.84 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE